



INNOVATION Kyoto 2016 Investment Limited Partnership Invests in Chordia Therapeutics Inc.

Kyoto, Japan, November 22, 2017 – Innovation Kyoto 2016 Investment Limited Partnership (“KYOTO-iCAP 1st Fund”), and Kyoto University Innovation Capital Co., Ltd. (the general partner. Headquarters: Sakyo-ku, Kyoto City; CEO: Koji Murota; “KYOTO-iCAP”), announced today it has concluded an investment contract with Chordia Therapeutics Inc. (Headquarters: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake; “Chordia”), a venture company utilizing research results from Kyoto University.

Chordia was founded by six scientists and is headed by Dr. Hiroshi Miyake, who previously led oncology drug discovery research at Takeda Pharmaceutical Company Limited [TSE: 4502] (“Takeda”). Chordia is focusing on the research and development of novel anti-cancer drugs. Dr. Miyake’s group has collaborated on multiple programs with Professor Seishi Ogawa of Graduate School of Medicine and Faculty of Medicine Kyoto University (Department of Pathology and Tumor Biology), based on Prof. Ogawa’s world-class research in oncology genomics. Here, collaborations of Takeda with Prof. Ogawa transfers to those of Chordia.

KYOTO-iCAP values Chordia's management philosophy of delivering new therapeutic drugs to patients suffering from refractory cancer and the high potential value of its pipeline. Under the terms of the investment contract, KYOTO-iCAP will receive a portion of the third-party shares allocated by Chordia. Takeda Pharmaceutical Co., Ltd., SMBC Venture Capital Co., Ltd., and Mitsubishi UFJ Capital Co., Ltd. are other companies subscribing to the third-party share allocation.

KYOTO-iCAP will disclose other investment details with Chordia, soon.

Overview of Chordia Therapeutics Inc.

Date established	10/12/2017
Scope of business	Research and development of new anti-cancer drugs
Location	Fujisawa City, Kanagawa Prefecture
CEO	Hiroshi Miyake

About Kyoto University Innovation Capital Co., Ltd. (“Kyoto iCAP”)

KYOTO-iCAP is a wholly owned subsidiary of Kyoto University established in December 2014. Its purpose is to provide investment and support to companies founded by researchers belonging to Kyoto University (including spin-offs from joint research companies) for



commercializing knowledge (including research results, technology, etc.). The KYOTO-iCAP 1st Fund was created from a 16-billion-yen capital contribution from Kyoto University and private financial institutions, in January 2016. KYOTO-iCAP is a general partner of the Fund. The fund management period is 15 years, that enables KYOTO-iCAP to support Kyoto University-originated ventures with long-term and to provide equity from the seed stage to practical application. The university is one of the top research institution in Asia.

【Contact Information】

Kyoto University Innovation Capital Co., Ltd.

36-1 Yoshida Honmachi, Sakyo-ku, Kyoto 606-8317 Japan

Kyoto University International Science Innovation Building, East Building, 4th Floor

Head of Media Relations : Osami Kono

Tel: +81-(0)75-753-5303, Fax: +81-(0)75-753-7592

Email: info@kyoto-unicap.co.jp